J&J, Guidant To Benefit From Medtronic's Rapid Exchange Market Pull-Out
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's immediate withdrawal from the rapid exchange delivery market in the U.S. opens the door for Johnson & Johnson/Cordis to take over the number-two spot in the coronary stent market.
You may also be interested in...
Medtronic Licensing Deal With Abbott Is Hawkins’ First Test: Results Pending
William Hawkins' initial stamp on Medtronic's struggling AVE vascular business includes a licensing deal with Abbott Laboratories for a drug-eluting stent compound and an unrelated restructuring of the operating unit, both announced May 9
Medtronic Licensing Deal With Abbott Is Hawkins’ First Test: Results Pending
William Hawkins' initial stamp on Medtronic's struggling AVE vascular business includes a licensing deal with Abbott Laboratories for a drug-eluting stent compound and an unrelated restructuring of the operating unit, both announced May 9
Guidant v. Medtronic
Guidant is awarded $158 mil. in damages from Medtronic subsidiary Arterial Vascular Engineering for infringement of rapid-exchange dilatation catheter and stent system delivery technology patents under an arbitration panel ruling April 25. Medtronic was ordered to stop sales of its rapid-exchange products in September under a separate patent infringement suit brought by Boston Scientific (1"The Gray Sheet" Sept. 24, 2001, p. 9). Medtronic says the expense will be recorded in the company's fourth fiscal quarter...